II. Indications
-
HIV Infection
- Anti-retroviral naive or experienced patients as part of combination therapy
III. Mechanism
- Anti-retroviral agent
- Integrase Strand Transfer Inhibitor
- Prevents viral DNA from integrating into host DNA
- Blocks the integrase enzyme
IV. Medications: Single Agents
-
Bictegravir
- Only available as combination agent
- Biktarvy contains Bictegravir (an InSTI) and 2 nRTI agents, Emtricitabine (FTC), Tenofovir (TAF)
-
Cabotegravir (Vocabria)
- See Cabotegravir
- Cabenuva (Cabotegravir and Rilpivirine) IM Monthly Injection is used for HIV Infection Treatment
- Cabotegravir (Apretude) IM Monthly Injection is indicated in HIV Pre-exposure Prophylaxis or PReP
-
Dolutegravir (Tivacay)
- See Dolutegravir
- Dolutegravir and Lamivudine (Dovato)
- Dolutegravir 50 mg AND Rilpivirine 25 mg (Juluca)
- Raltegravir (Isentress)
V. Safety
-
Lactation
- Unknown safety in Lactation
- Pregnancy
- Dolutegravir (Tivacay)
- Unsafe in pregnancy
- Associated with Neural Tube Defects
- May be a class effect (unclear if this applies to other Integrase Inhibitors)
- Dolutegravir (Tivacay)
VI. Efficacy
- Drug resistance is common
VII. Adverse Effects: General
- Weight gain
- Hyperglycemia
- Hyperlipidemia
- Weight gain (2 to 7 kg, more in women)
VIII. Adverse Effects: Raltegravir
- Diarrhea
- Nausea
- Headache
- Serum Creatinine phosphokinase (CPK) increases
- Mild Serum Creatinine increase without affecting Renal Function (Dolutegravir)
- Myopathy
- Rhabdomyolysis
- Insomnia
- Liver Function Test abnormalities (Cabotegravir)
IX. Drug Interactions
- Typically fewer Drug Interactions than other Anti-Retroviral Agents
- Phenytoin
- Rifampin
- St John's Wort
- Avoid taking at the same time as Calcium, Magnesium, aluminum and iron containing agents